Healios K.K
Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ische… Read more
Healios K.K (HLOSF) - Net Assets
Latest net assets as of December 2025: $4.90 Billion USD
Based on the latest financial reports, Healios K.K (HLOSF) has net assets worth $4.90 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.07 Billion) and total liabilities ($12.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.90 Billion |
| % of Total Assets | 28.73% |
| Annual Growth Rate | 5.7% |
| 5-Year Change | -43.28% |
| 10-Year Change | -18.2% |
| Growth Volatility | 98.32 |
Healios K.K - Net Assets Trend (2014–2025)
This chart illustrates how Healios K.K's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Healios K.K (2014–2025)
The table below shows the annual net assets of Healios K.K from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.90 Billion | +135.28% |
| 2024-12-31 | $2.08 Billion | -46.12% |
| 2023-12-31 | $3.87 Billion | -11.73% |
| 2022-12-31 | $4.38 Billion | -49.31% |
| 2021-12-31 | $8.64 Billion | +10.11% |
| 2020-12-31 | $7.85 Billion | -12.55% |
| 2019-12-31 | $8.98 Billion | -16.73% |
| 2018-12-31 | $10.78 Billion | -33.29% |
| 2017-12-31 | $16.16 Billion | +169.65% |
| 2016-12-31 | $5.99 Billion | -36.08% |
| 2015-12-31 | $9.38 Billion | +251.91% |
| 2014-12-31 | $2.66 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Healios K.K's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 143241261200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.00 Billion | 20.45% |
| Common Stock | $2.57 Billion | 52.60% |
| Other Comprehensive Income | $-1.72 Billion | -35.19% |
| Other Components | $3.04 Billion | 62.15% |
| Total Equity | $4.89 Billion | 100.00% |
Healios K.K Competitors by Market Cap
The table below lists competitors of Healios K.K ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enli Technology Co.,Ltd
TWO:7728
|
$116.23 Million |
|
Qijing Machinery
SHG:603677
|
$116.25 Million |
|
MK Electron Co. Ltd
KQ:033160
|
$116.29 Million |
|
Forest Packaging Group Co Ltd
SHG:605500
|
$116.30 Million |
|
Swedencare AB (publ)
OTCQX:SWDCF
|
$116.19 Million |
|
Crexendo Inc
NASDAQ:CXDO
|
$116.12 Million |
|
Design Milk Co Limited
PINK:AHAHF
|
$116.11 Million |
|
Black Spade Acquisition II Co
NASDAQ:BSII
|
$116.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Healios K.K's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,063,000,000 to 4,894,267,072, a change of 2,831,267,072 (137.2%).
- Net loss of 2,218,934,580 reduced equity.
- Share repurchases of 2,001,745 reduced equity.
- Other comprehensive income increased equity by 4,498,235.
- Other factors increased equity by 5,047,705,162.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.22 Billion | -45.34% |
| Share Repurchases | $2.00 Million | -0.04% |
| Other Comprehensive Income | $4.50 Million | +0.09% |
| Other Changes | $5.05 Billion | +103.14% |
| Total Change | $- | 137.24% |
Book Value vs Market Value Analysis
This analysis compares Healios K.K's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $67.06 | $1.94 | x |
| 2015-12-31 | $250.57 | $1.94 | x |
| 2016-12-31 | $147.23 | $1.94 | x |
| 2017-12-31 | $361.47 | $1.94 | x |
| 2018-12-31 | $218.98 | $1.94 | x |
| 2019-12-31 | $179.07 | $1.94 | x |
| 2020-12-31 | $152.55 | $1.94 | x |
| 2021-12-31 | $164.27 | $1.94 | x |
| 2022-12-31 | $76.86 | $1.94 | x |
| 2023-12-31 | $56.70 | $1.94 | x |
| 2024-12-31 | $23.32 | $1.94 | x |
| 2025-12-31 | $45.46 | $1.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Healios K.K utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2131.73%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 3.49x
- Recent ROE (-45.34%) is above the historical average (-65.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -17.91% | -170.45% | 0.09x | 1.19x | $-743.72 Million |
| 2015 | -10.22% | -975.99% | 0.01x | 1.12x | $-1.90 Billion |
| 2016 | -57.28% | -4422.40% | 0.01x | 1.53x | $-4.03 Billion |
| 2017 | -10.99% | -6421.79% | 0.00x | 1.22x | $-3.39 Billion |
| 2018 | -47.27% | 0.00% | 0.00x | 1.39x | $-6.18 Billion |
| 2019 | -49.11% | -4953.93% | 0.00x | 2.35x | $-5.31 Billion |
| 2020 | -70.28% | -20418.52% | 0.00x | 2.95x | $-6.30 Billion |
| 2021 | -56.86% | -11980.49% | 0.00x | 2.77x | $-5.78 Billion |
| 2022 | -117.98% | -5744.44% | 0.01x | 3.43x | $-5.61 Billion |
| 2023 | -99.14% | -3159.50% | 0.01x | 3.93x | $-4.21 Billion |
| 2024 | -205.28% | -756.25% | 0.04x | 6.88x | $-4.44 Billion |
| 2025 | -45.34% | -2131.73% | 0.01x | 3.49x | $-2.71 Billion |
Industry Comparison
This section compares Healios K.K's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Healios K.K (HLOSF) | $4.90 Billion | -17.91% | 2.48x | $116.20 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |